Compare TWIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | SKYE |
|---|---|---|
| Founded | 1918 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 9.0M |
| IPO Year | 1994 | 2013 |
| Metric | TWIN | SKYE |
|---|---|---|
| Price | $24.90 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 92.3K | ★ 516.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 1428.57 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $381,270,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $13.19 | ★ N/A |
| Revenue Growth | ★ 11.90 | N/A |
| 52 Week Low | $13.02 | $0.26 |
| 52 Week High | $25.50 | $4.99 |
| Indicator | TWIN | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 64.80 |
| Support Level | $22.13 | $0.66 |
| Resistance Level | $24.28 | $2.32 |
| Average True Range (ATR) | 0.97 | 0.18 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 70.80 | 51.64 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.